Portfolio News
- February 02, 2012 Preglem PEARL I and II studies published in New England Journal of Medicine
- January 23, 2012 Trius Earns $5 Million Milestone Payment From Bayer for Successful Completion of First Phase 3 Trial of Tedizolid
- January 05, 2012 Pfizer Initiates Phase 1 Clinical Trial For Fviia Hemophilia Drug Candidate Developed By Catalyst Biosciences IND Filing and Phase 1 Clinical Trial Initiation Trigger Milestone Payments to Catalyst
- December 20, 2011 Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
- December 19, 2011 Trius Reports Positive Results From First Phase 3 Trial of Tedizolid in Acute Bacterial Skin and Skin Structure Infections
- December 16, 2011 Richter announces that PregLem, its wholly owned subsidiary, receives positive EMA/CHMP opinion for Esmya® for the pre-operative treatment of uterine fibroids (myomas)
- December 09, 2011 Crocus and SMIC Sign Technology Development and Wafer Manufacturing Agreements
- November 29, 2011 Alvine’s ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year
- November 21, 2011 Amarin Added to NASDAQ Biotechnology Index
- November 18, 2011 One-on-One with Dan Adelman of Alvine Pharmaceuticals
- November 10, 2011 Crocus and Morpho Sign Agreement to Develop Smart Cards Based on Magnetic-Logic-UnitT (MLU) Technology
- November 02, 2011 Volubill Named One of the Best Private Companies in Light Reading’s 2011 Leading Lights Awards
- October 31, 2011 Intellikine Earns $4 Million in Milestone Payments for Initiation of Two Phase 1 Clinical Trials for IPI-145, a Potent Inhibitor of PI3Kdelta and PI3Kgamma
- October 27, 2011 Alvine Pharmaceuticals Announces Positive Results from Phase 2a Trial of ALV003 in Celiac Disease Patients
- October 25, 2011 Volubill Unveils Business and Network solutions for Service Provider Policy Management and Charging